Evox’s mission is to build a platform technology company spearheading the translation of exosome therapeutics for the treatment of serious, life-threatening diseases with limited options for patients and their families.
Exosomes are increasingly seen as foundational transporters in the human body’s own communication machinery and Evox’s technology development is unwaveringly focused on exploiting this natural mechanism for creating a novel form of biotherapeutics. Exosomes have been shown to be able to transport various types of biomacromolecules – for instance protein and RNA therapeutics – but also various types of small molecule drugs. Evox combines the highly versatile delivery capabilities of exosomes with targeting technology, sophisticated biomolecular engineering approaches, and large-scale production methodology, to enable the development of natural delivery nanoparticles for the treatment of severe diseases with validated therapeutic targets.
With its roots firmly grounded in two world-renowned academic institutions – the University of Oxford and the Karolinska Institute – Evox is driven by a dedication to scientific excellence and to pushing the scientific frontier together with an ecosystem of academic partners and collaborators worldwide (LINK TO EVOX’S ECOSYSTEM)ncing exosome-mediated delivery to tissues of interest and combining this with the inherent biology of exosomes to further drive optimal in vivo behavior.